Amgen's Repatha Receives Positive Opinion for Cardiovascular Risk Reduction

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion supporting the broader use of Amgen's Repatha® (evolocumab) to reduce the risk of a first heart attack or stroke. This recommendation is based on the drug's demonstrated efficacy in significantly reducing major cardiovascular events, as confirmed in a large Phase 3 clinical trial.

The CHMP's assessment focused on Repatha's ability to lower the risk of the first heart attack or stroke in patients with high cholesterol and established cardiovascular disease, or with familial hypercholesterolemia. Repatha is a PCSK9 inhibitor, uniquely proven to reduce primary cardiovascular events.

This positive opinion marks a significant step towards improving access to Repatha in Europe. It may lead to wider prescription by physicians for patients requiring potent LDL cholesterol lowering and at elevated risk of cardiovascular disease, potentially altering current prevention practices.

Amgen now awaits a final decision from the European Commission, which would allow the drug to be officially marketed with the expanded indication across the European Union. This follows the validation of clinical evidence showing Repatha's potential to redefine cardiovascular risk management.